A case-control study estimating accident risk for alcohol, medicines and illegal drugs by Kuypers, Kim et al.
A Case-Control Study Estimating Accident Risk for
Alcohol, Medicines and Illegal Drugs
Kim Paula Colette Kuypers1,2*, Sara-Ann Legrand2, Johannes Gerardus Ramaekers1, Alain
Gaston Verstraete2
1Department of Neuropsychology & Psychopharmacology, Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, The Netherlands, 2Department of
Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium
Abstract
Background: The aim of the present study was to assess the risk of having a traffic accident after using alcohol, single drugs,
or a combination, and to determine the concentrations at which this risk is significantly increased.
Methods: A population-based case-control study was carried out, collecting whole blood samples of both cases and
controls, in which a number of drugs were detected. The risk of having an accident when under the influence of drugs was
estimated using logistic regression adjusting for gender, age and time period of accident (cases)/sampling (controls). The
main outcome measures were odds ratio (OR) for accident risk associated with single and multiple drug use. In total, 337
cases (negative: 176; positive: 161) and 2726 controls (negative: 2425; positive: 301) were included in the study.
Results: Main findings were that 1) alcohol in general (all the concentrations together) caused an elevated crash risk; 2)
cannabis in general also caused an increase in accident risk; at a cut-off of 2 ng/mL THC the risk of having an accident was
four times the risk associated with the lowest THC concentrations; 3) when ranking the adjusted OR from lowest to highest
risk, alcohol alone or in combination with other drugs was related to a very elevated crash risk, with the highest risk for
stimulants combined with sedatives.
Conclusion: The study demonstrated a concentration-dependent crash risk for THC positive drivers. Alcohol and alcohol-
drug combinations are by far the most prevalent substances in drivers and subsequently pose the largest risk in traffic, both
in terms of risk and scope.
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Introduction
Alcohol and cannabis are amongst the substances most widely
used by drivers in Europe [1,2,3]. A recent roadside study in 13
European countries revealed that alcohol was the most prevalent
(3.48%) among drivers, followed by illicit drugs (1.9%, with
cannabis most frequently detected), and medicinal drugs (1.36%)
[1]. Legitimate concern exists about the influence of alcohol and
other drugs on traffic safety. By means of epidemiological studies,
the risk of having an accident (risk assessment; case-control studies)
and the risk of being responsible for a crash (responsibility or
culpability estimates; also called case-crossover studies) can be
calculated. Both are valid methods to study and understand the
impact of drug use on traffic safety. Culpability studies have been
conducted in larger numbers than case-control studies, which are
scarcer, probably due to their high costs and complex logistics
[4,5].
Culpability studies focus on drivers involved in traffic accidents
and classify each case according to the driver’s responsibility (yes/
no) for the accident and the presence of drugs (positive/negative).
These data are then taken to calculate the culpability risk for
drivers under the influence of drugs. The assumption is that
driving under the influence increases the risk of being responsible
for causing a traffic crash [2,6]. In general, culpability studies have
indicated that alcohol as well as alcohol-drug and drug-drug
combinations are associated with significantly elevated risks [5].
Case-control studies compare prevalence of drug use among
drivers involved in crashes (i.e. cases) and among a control group
that was not involved in traffic accidents. The assumption is that
drugs that cause driver impairment will be more prevalent in cases
than in controls, which can be expressed as an OR of crash risk.
Ideally the control group consists of a random sample of drivers
from the general driving population, but alternative approaches
have been used. Mura and colleagues (2003) did not randomly
select drivers as controls but instead used non-traffic involved
patients with a valid driver licence [7]. A potential shortcoming of
this approach is that the controls might not be a correct
representation of the driving population. A population-based
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case-control study on the other hand gathers information from the
general driving population (e.g. by means of roadside testing), and
from fatally and/or non-fatally injured drivers. Both populations
are screened for alcohol and drugs. Using these data, OR are
calculated to estimate the accident risk associated with a specific
(or combination of) substance(s) [2,4,6,8]. This kind of design is
preferable over the non-random selection of controls as it reflects
the true driving population but only a limited number of such
studies have been conducted in injured and killed drivers [4,9,10].
The present study is a population-based case-control study in
which controls were randomly selected drivers in the same regions
where the accidents happened.
Another potential shortcoming in previously conducted studies
has been the use of different matrices to determine drug presence
in cases and controls. Ideally, drug presence is determined in the
same matrix, preferably blood, in order to maximize comparabil-
ity. Comparisons of drug concentrations in distinct matrices are
troublesome due to a lack of reliable transfer functions [11,12],
differences in detection windows, or due to the inability to measure
the parent compound in some matrices [4]. Unfortunately, most
case-control studies used different matrices in cases and controls,
and compared blood data collected in cases to saliva [9] or urine
[13] data from controls (review: [10]). As a consequence, many
case-control studies have not been able to determine concentra-
tion-effect relations between drug use and crash risk [7]. In order
to overcome this difficulty, the present study collected blood
samples in both cases and controls.
The data presented in this article are part of a large-scale
European project called ‘‘Driving under the influence of Drugs,
Alcohol, and Medicines’’ (DRUID; www.druid-project.eu). The
main aim of the project was to assess drug prevalence in traffic and
their associated risk. Likewise, the objective of the present study
was to calculate the risk of having a car accident after using a drug,
or a combination of different drugs. The general hypothesis was
that drug use increases accident risk.
Methods
Setting, Data Collection, and Study Population
A population-based case-control study was conducted in
Belgium from 2008 till 2010. The detailed description of the
procedure has been published [14].
Cases were drivers involved in an accident, and who were
hospitalized in five hospitals in Belgium (University Hospitals of
Brussels, Ghent, Leuven and Lie`ge and regional hospital of
Namur). These hospitals were involved in the Belgium Toxicology
and Trauma Study of 1995 [15]. A total of 1078 blood samples
from injured drivers were collected and delivered to the laboratory
with the corresponding patient form. Medical staff was in charge
of filling out a patient form for each participant. The patient form
included the minimum required data, i.e.: Maximum Abbreviated
Injury Scale (MAIS); identification number; hospital; date and
time of the accident; vehicle type; drugs and fluids administered in
hospital before sampling; age and gender of patient; time between
accident and sampling; single or multiple vehicle accident.
Controls were a random sample of drivers on Belgian roads
(roadside survey), conducted in five regions corresponding to the
catchment areas of the hospitals. The procedure of this roadside
survey consisted of two independent phases. The first was a
random alcohol control performed by the police. The police
officers were asked not to pay attention to external signs of
impairment but to stop drivers at random and to test all stopped
drivers. After the police procedure (amongst other: alcohol test
with breathalyser), the stopped drivers were asked if they wanted
to participate in the present research. If they refused, a refusal
form with demographic data was filled in to be able to calculate a
response rate. The second phase was the blood sample collection,
which took place in a mobile research unit. The drivers were
informed about the objective and the content of the research,
signed an informed consent form, and were asked to fill in a
questionnaire, to give a saliva sample and a blood sample, which
was taken by a nurse. The questionnaire asked for the following
information: type of vehicle, gender, age, education level, the
result of the breathalyser test, drug control or other observations
made by the police, and self report about drug, alcohol, and
medicine use. Respondents who participated in the study were
given a gift voucher of J20.
In total, 6163 drivers were stopped by the police. Fifty-two
percent of them refused to participate, 48% agreed. The majority
of respondents agreed to give both a blood and a saliva sample
(93.13%), 6.73% gave only a saliva sample, 0.14% only a blood
sample. In the present study, only respondents who provided a
blood sample (93.27%) were included.
The study protocols of both studies were approved by the ethics
committee of Ghent University Hospital. All subjects gave written
informed consent. The toxicological and patient data were
separated from the clinical files and made anonymous in order
to guarantee the privacy of the patients.
Based on a number of criteria, cases and controls were selected
from the original sample to be included in the present study. These
criteria were: only car & van (as controls were restricted to those
two types of vehicles) and Maximum Abbreviated Injury Scale
(MAIS) $2, as a MAIS below 2 indicates only minor injury and
we were interested in more serious injuries [16,17]. The time
between accident and sampling was never longer than 4 hours.
Negative cases and controls were negative for all tested substances
in blood.
Based on the above-mentioned selection criteria, 337 cases
(negative: 176; positive: 161) and 2726 controls (negative: 2425;
positive: 301) were included in the study (Fig. 1; Table 1). In both
groups, the prevalence of alcohol was the highest, followed by the
combination of alcohol and sedatives for the cases and benzodi-
azepines for the controls.
Toxicological Analysis of Blood Samples
Twenty-six substances were determined in whole blood and
grouped into drug categories (table 2). In case of metabolites, these
were always accompanied by the core substance in order to be
found positive. The analyses were performed by validated
chromatographic methods, coupled to (tandem) mass spectrometry
[18,19].
Statistical Analysis
Statistical analyses were performed by means of PASW Statistics
version 18.0. Binary logistic regression with the Backward
Stepwise Likelihood Ratio method was used to calculate crude
and adjusted OR. First, it uses the likelihood ratio statistic to
determine which predictors form the best model. In addition, the
backward stepwise method is preferable to the forward selection as
the former has a lower risk of Type II error [20].
The dependent variable was accident (yes/no), and covariates
were: drug (yes/no) for the crude and the adjusted OR, and also 3
extra variables for the adjusted OR: age, gender and time of week
on which the accident (cases) or the roadside control (controls) took
place (See Table 1). A statistically significant association between a
drug and an accident is indicated by a 95% confidence interval
that does not include 1. Variables that are not in the final equation
are those that did not significantly predicted the outcome; i.e.
Accident Risk for Different Types of Drugs
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accident risk. Due to the low number of cases/controls in most of
the drug categories, interaction effects between drug and gender,
and drug and time period, were not included in the analyses.
Before entering the analyses, the included variables were
weighted. As the distribution of the study sample in the roadside
study was disproportionate to the distribution of the general
driving population in the eight time periods, this had to be
corrected. To that end, weight factors were calculated by dividing
the general distribution of traffic by time period by the distribution
of sampled drivers in the same time period. The data on the
general distribution of traffic was based on traffic counts of the
Flemish government Agency Roads and Traffic of 2007 (http://
bestuurszaken.be/AWV). The calculated weights ranged between
0.025 and 0.187 for the 8 different time periods. For the cases, this
weight was set at 1, as all accidents were registered in the sampling
period in the prescribed regions.
The number of cases and controls included in the calculation of
the adjusted OR was less than those included in the crude OR.
Some of the cases/controls were excluded because of missing
demographic data (age/gender/time period) (see Table 1). For
drug categories with empty cells for either positive controls or
cases, only crude OR were calculated. In order to be able to
calculate the risk, one observation was added to the four cells.
All the OR that are mentioned under results are adjusted ORs,
except when stated otherwise. In case time period contributed
significantly to the model, OR were calculated again, including the
parameter week (periods 1–4) –weekend (periods 5–8) or day
(periods 1–3+5–7)-night (4+8) as a covariate. For alcohol and
cannabis, concentrations were grouped into 4 and 3 concentration
categories respectively (alcohol: 0.1–0.5; 0.51–0.8; 0.81–1.2 and
.1.2 g/L; cannabis: 1–1.99, 2–4.99, and $5 ng/mL). The
concentration groupings of alcohol were based on the legal limits
for driving under the influence of alcohol. In most countries, there
is a 0.5- concentration limit, in some a 0.8-concentration limit.
The same grouping has also been used in previous epidemiological
and experimental studies [7,21,22,23]. The concentration group-
ings for THC were based on experimental research showing a cut-
off of 2 and 5 ng/mL to be linked with driving-related behavioural
impairment [24]. ORs were calculated for the whole range of
concentrations and for the concentration groups separately. The
latter approach allows determining cut-offs for alcohol and
cannabis at which the accident risk significantly increases.
Results
Single Drugs
Alcohol. The OR for all alcohol concentrations (0.12
.1.2 g/mL) was statistically significant (p,.001). Including
alcohol concentration groups into the model revealed a breaking
point at 0.8 g/L, at which the risk of having an accident
significantly (p,0.001) increased (see Table 2). All the included
parameters except gender contributed significantly to the
models. The contribution of age to accident risk was further
analyzed including 2 age groups: a ‘young’ group (18–34) and
an ‘old’ group (35–50+), the latter used as reference. The crash
Figure 1. Flow chart depicting the selection procedure for the cases (left) and controls (right) included in the present study. Study
selection criteria for cases: MAIS $2; Type of vehicle (car/van); Time between accident and sampling (,4 h).
doi:10.1371/journal.pone.0043496.g001
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risk was higher in the ‘young’ group (OR: 2.07; CI: 1.58–2.71).
There was no significant interaction between age group and
drug, indicating that the effects of age and drug use on crash
risk were independent of each other. The contribution of time
period to accident risk was further analyzed including two
groups: week-weekend or day-night. There was a higher risk of
having an accident at night (OR: 2.85; CI: 2.04–3.99; p,.001)
or in the weekend (OR: 1.58; CI: 1.20–2.09; p= .001)
compared to day and week, respectively.
Cannabis. The OR for all the THC concentrations (12
.5 ng/mL) was statistically significant (p,.001). Including
cannabis group into the model revealed a THC concentration
breaking point at 2 ng/mL, at which the risk of having an accident
was significantly increased. All the included parameters except for
age contributed significantly to the models. Further analyses for
gender and time period showed that accident risk was elevated for
men (OR: 1.390; CI: 1.011–1.910; p= .043), at weekends (OR:
1.42; CI: 1.01–1.99; p= .043) and at nights (OR: 3.01; CI: 1.98–
4.58; p,.001), independent of drug.
Amphetamines. The crude OR for Amphetamines was
54.82 (p,.001) depicting an increased crash risk when under the
influence of, or after having taken, amphetamines.
Benzoylecgonine, Cocaine, and Illicit Opiates. The crude
OR for Benzoylecgonine, Cocaine and Illicit Opiates were not
statistically significantly increased.
Benzodiazepines, Z-drugs &Medicinal Opiates. The OR
for Medicinal Opiates was not statistically significant, but there
was a trend, i.e. p = .056, suggesting an increase in accident risk
Table 2. Main drug categories, analytical findings & substances, and their cut-offs.
Main category Analytical Findings Analytical substance
Whole blood analytical
cut-offs (ng/mL)
Alcohol Ethanol Ethanol 0.1 g/L
Amphetamines Amphetamine, Methamphetamine or
Methamphetamine+Amphetamine, MDMA or
MDMA+MDA, MDEA or MDEA+MDA, MDA
Amphetamine 20
Methamphetamine 20
MDMA 20
MDA 20
MDEA 20
Benzodiazepines Diazepam+Nordiazapam or Diazepam+Oxazepam or
Diazepam+Nordiazepam+Oxazepam, Nordiazapam or
Nordiazepam+Oxazepam, Oxazepam, Lorazepam, Alprazolam,
Flunitrazepam or Flunitrazepam+7- aminoflunitrazepam,
Clonazepam or Clonazepam +7-aminoclonazepam
Diazepam 20
Nordiazepam 20
Oxazepam 50
Lorazepam 10
Alprazolam 10
Flunitrazapam 2
7-aminoflunitrazepam 2
Clonazapam 10
7-aminoclonazepam 10
Cannabis THC or THC+THCCOOH THC 1
THCCOOH 5
Cocaine Cocaine+Benzoylecgonine or Cocaine Cocaine 10
Benzoylecgonine 50
Illicit opiates 6-acetylmorphine or 6-AM+Codeine or
6-AM+Morphine or 6-AM+Codeine+Morphine
or (Morphine+Codeine and Morphine
concentration.=Codeine)
6-acetylmorphine (AM) 10
Morphine 10
Codeine 10
Medicinal opiates and opioids Morphine, Codeine or (Codeine+Morphine and Codeine
concentration.Morphine concentration), Methadone, Tramadol
Morphine 10
Codeine 10
Methadone 10
Tramadol 50
Z-drugs Zolpidem, Zopiclone Zolpidem 20
Zopiclone 10
doi:10.1371/journal.pone.0043496.t002
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when driving under the influence of Medicinal Opiates. Time
period contributed significantly to the model, with a higher risk of
accident in the weekend.
The OR for Benzodiazepines and Z-drugs could not be
calculated as the parameter drug did not contribute significantly
to the model, indicating that the drug did not significantly explain
the variance in the dependent variable, accident.
Multiple Drugs
The OR for the combination of sedatives or stimulants with
alcohol, combinations of multiple sedatives (p = .001) and sedatives
and stimulants (p = .005) were statistically significant (see Table 3).
All the OR indicated an increased crash risk. All the included
parameters except for age contributed significantly to the models
with an increased accident risk, independent of drug, for men, at
weekends, and at nights. These analyses for time period (day-
night/week-weekend) were not possible for ‘sedatives and stimu-
lants’; and for ‘alcohol and stimulants’ (week-weekend) as there
were no observations in some categories.
No OR was calculated for ‘multiple stimulants’ as there were no
positive cases, nor controls in this category.
Discussion
This population-based case-control study was conducted in
order to gain insight into the accident risk associated with drug
use, collecting blood of both cases and controls that was analyzed
for alcohol and a number of drugs.
Alcohol, independent of concentration, was related to an
increase in accident risk. This finding was expected, and in line
with previously reported studies (e.g. [9,25]). We did not find a
significantly increased OR for BAC concentrations between 0.5–
0.8 g/L. This is in contrast with other reports [25] that showed
elevated OR with this BAC range. In the present study, the OR
(2.13) did approach significance (p= 0.092) indicating a trend
towards increased risk. Possibly the low number of cases in this
particular BAC range hampered a reliable estimation of the
associated risk [26,27]. Combined alcohol-drug use was 3 times
higher in cases as compared to controls in this particular BAC
range. The present data largely confirm the findings of the Grand
Rapid study, and its replication in 2005 [28,29]. Both showed a
high risk for blood alcohol concentrations $0.8 g/L and the risk
increased extremely above 1.5 g/L.
Overall, cannabis increased crash risk of drivers positive for
THC. These findings fit previous culpability and case-control
Table 3. Number of weighed controls and not-weighed cases per substance & associated odds ratio.
Adjusted odds ratioo Crude odds ratio
Substances-Groups Cases Controls OR 95% CI p Cases Controls OR 95% CI p
Negative 168 2449.51 – – – 176 2466 – – –
Single drugs
Alcohol-overall 95 175.80 6.77 4.99–9.18 ,.001 99 176 7.87 5.887–10.51 ,.001
BAC-group 1 (0.1–0.5 g/L) 8 113.47 0.98 .47–2.05 Ns 8 115 .97 .47–2.03 Ns
BAC-group 2 (0.5–0.8 g/L) 6 37.74 2.13 .88–5.16 .092 6 38 2.23 .93–5.34 .073
BAC-group 3 (0.8–1.2 g/L) 8 11.56 9.56 3.80–24.07 ,.001 9 12 10.91 4.50–26.42 ,.001
BAC-group 4 (.1.2 g/L) 73 12.03 76.41 40.05–145.80 ,.001 76 12 88.52 47.28–165.73 ,.001
Amphetamines – – – – – 4{ 1{ 54.82 6.09–493.12 ,.001
Benzoylecgonine – – – – – 1{ 5{ 6.85 0.62–75.94 Ns
Cocaine – – – – – 1{ 2{ 2.74 0.32–23.59 Ns
Cannabis-overall 5 5.79 13.40 3.95–45.42 ,.001 5 6 12.10 3.62–40.43 ,.001
Group 1 (1–1.99 ng/mL 1 2.40 6.64 .63–69.59 Ns 1 2 5.84 .56–60.48 Ns
Group 2 (2–4.99 ng/mL) 2 1.26 24.83 2.58–238.93 .005 2 1 22.24 2.38–207.77 .007
Group 3 ($5 ng/mL) 2 2.13 14.32 2.03–101.13 .008 2 2 13.16 1.90–91.18 .009
Illicit Opiates – – – – – 1{ 3{ 4.57 0.47–44.15 Ns
Benzodiazepines 5 52.17 – – – 5 52 1.34 .53–3.40 ns
Z-Drugs 2 6.52 – – – 3 7 6.45 1.63–25.52 .008
Medicinal Opiates 4 19.50 2.91 0.97–8.68 .056 4 20 3.42 1.27–9.21 .015
Multiple Drugs
Alcohol+Sedatives 24 4.50 67.19 23.91–188.84 ,.001 28 5 87.19 31.85–238.69 ,.001
Alcohol+Stimulants 5 3.27 20.34 4.93–83.82 ,.001 6 3 25.71 6.63–99.76 ,.001
Multiple Stimulants – – – – – – – – – –
Multiple Sedatives 3 3.83 13.70 2.95–63.66 .001 3 4 10.98 2.40–50.12 .002
Stimulants+Sedatives 5 .29 210.97 4.90–9088.71 .005 5 .29 241.51 5.7–10239.30 .004
Legend: ns = not statistically significant; adjusted odds ratioo: after removal of missing data for gender, age, & time period; {: 1 observation was added to each of the four cells;
Alcohol & Sedatives ( = Alcohol +: THC, Benzodiazepines, THC & Benzodiazepines, Benzodiazepines & Z-drugs, Medicinal opiates), Alcohol and Stimulants ( = Alcohol +:
Amphetamines, Benzoylecgonine, Cocaine, Amphetamines & Cocaine) Multiple Sedatives (Benzodiazepine & Z-drugs, THC & Medicinal Opiates, Benzodiazepines & Medicinal
Opiates) and Stimulants & Sedatives (Benzoylecgonine & THC, Amphetamines & Benzoylecgonine & THC, Amphetamines & Cocaine & THC, Amphetamines & THC &
Benzodiazepines, Benzoylecgonine & Medicinal Opiates).
doi:10.1371/journal.pone.0043496.t003
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studies that have reported that drivers under the influence of THC
are at increased risk of becoming involved in a crash [6,25]. The
THC-induced crash risk became prominent for a THC concen-
tration .2 ng/mL. The latter seems in line with previous
epidemiological reports. Laumon and colleagues (2005) showed
a THC increase in culpability risk for a THC concentration
.2 ng/mL [30]. Khiabani and colleagues (2006) showed that
drivers who were judged to be impaired had a median THC blood
concentration of 2.5 ng/mL which differed significantly from
drivers that were judged to be not impaired (1.9 ng/mL) [31].
Experimental data previously also demonstrated that THC
induced an increase in performance impairments at low concen-
trations. Serum THC concentrations between 2 and 5 ng/mL
have been identified as a threshold above which THC induced
impairment of skills related to driving become apparent [24].
OR for intermediate THC levels appeared higher as compared
to higher levels of THC. It should be noted here that absolute OR
levels are likely to be affected by the low number of cases in each
THC concentration range. This was also indicated by the very
wide confidence intervals associated with the OR [27]. In this
context, the finding that crash risk increased in a concentration
dependent manner (i.e. at low concentrations, not a significantly
elevated risk, at higher concentrations an elevated risk) may be
more relevant in the present study, than the absolute magnitude of
the risk. The latter is likely to become more accurate with higher
numbers of positive cases and controls.
The main strength of the present study was the use of the same
type of biological samples which made concentration-effect
relations possible. A potential weakness however was the fact that
we had no positive cases/controls for a number of substances (e.g.
amphetamines) and were therefore not able to calculate the
(adjusted) OR. This was addressed by adding an extra observation
in each of the four cells in order to calculate crude OR, i.e. not
adjusting for potential confounding variables. Only amphetamines
caused a statistically significant elevated crash risk. However, the
accompanying confidence interval was very wide and attributable
to the low number of positive cases and controls. Furthermore, the
other crude OR for benzoylegonine, cocaine, and illicit opiates (for
which there were no positive cases) showed elevated, but non-
significant OR. The results are in line with previous findings and
certainly do not show lowered risks (e.g. [25]).
A second potential limitation, interwoven with the main
strength of the study, is the consequence of collection of blood
samples. Due to this invasive procedure, the refusal rate or non-
response rate was high amongst controls. Fifty-two percent of them
refused to participate. Although these numbers are comparable to
other case-control studies [4], the risk of selection bias exists. This
can lead to an underestimation of the prevalence of drugs in the
general driving population and an overestimation of the risk
associated with particular drugs. Inspection of the demographic
variables of both groups showed that there were small but
significant differences between characteristics of participants and
refusers. Relative to cases, males were underrepresented and
females overrepresented in the control group. Likewise, partici-
pants in the age category 18–24 and 50+ were overrepresented
whereas 25–34 year olds were underrepresented in the controls.
For type of vehicle it was shown that vans were underrepresented.
For the majority of findings reasonable explanations can be
presented. For young people, the incentive (of J 20) was more
attractive than for the 25–34 year olds who have a busy life and an
income, and not much extra time to spend on unplanned things
like the present research. The under-representation of vans in the
control sample could be linked with time constraints as most of
those people are on the road for their work. There were no
differences in the prevalence of alcohol and the distribution in
BACs among study participants and non-respondents, suggesting
that the result of the alcohol test did not influence their decision to
participate or not. In addition, the latter could imply that ‘drug
use’ in general did not influence their decision to enter the study
and agree with the sample collection or not. However, it can not
be ruled out that the prevalence of medicines and drugs is higher
in the control group than currently reported. Therefore, the
emphasis must not be on the absolute values of the OR but on the
fact that elevated crash risks are associated with the reported drugs
in a concentration-related manner. Concentration-effect relations
are usually not influenced by refusal rate among controls and
therefore provide additional evidence for the association between
drug use and crash risk.
In conclusion, the study demonstrated that THC increased
crash risk in a concentration related manner. It was also shown
that alcohol and alcohol-drug combinations are by far the most
prevalent substances in drivers and subsequently pose the largest
risk in traffic both in terms of risk and scope.
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